Literature DB >> 30994574

Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.

Caroline S Dorfman1, Sarah S Arthur1, Gretchen G Kimmick1, Kelly W Westbrook2, Paul Kelly Marcom2, Cheyenne Corbett3, Sara N Edmond4,5, Rebecca A Shelby1.   

Abstract

OBJECTIVE: Past studies indicate that >90% of breast cancer survivors taking adjuvant endocrine therapy (AET) experience menopausal symptoms including sexual problems (eg, vaginal dryness, dyspareunia); however, research examining the impact of these problems on quality-of-life is limited. This cross-sectional study examined (1) the impact of sexual problems and self-efficacy for coping with sexual problems (sexual self-efficacy) on quality-of-life (ie, psychosocial quality-of-life and sexual satisfaction), and (2) partner status as a moderator of these relationships.
METHODS: Postmenopausal breast cancer survivors taking AET completed measures of sexual problems (Menopause-Specific Quality-of-Life [MENQOL] sexual subscale], sexual self-efficacy, psychosocial quality-of-life (MENQOL psychosocial subscale), and sexual satisfaction (Functional Assessment of Cancer Therapy-General item).
RESULTS: Bivariate analyses showed that women reporting greater sexual problems and lower sexual self-efficacy had poorer quality-of-life and less sexual satisfaction (all P-values < 0.05). Partner status moderated the relationship between sexual problems and psychosocial quality-of-life (P = 0.02); at high levels of sexual problems, unpartnered women experienced poorer psychosocial quality-of-life than partnered women. Partner status also moderated the relationship between self-efficacy and psychosocial quality-of-life (P = 0.01). Self-efficacy was unrelated to psychosocial quality-of-life for partnered women; for unpartnered women, low self-efficacy was associated with poorer quality-of-life. Partner status did not moderate the relationships between sexual problems or self-efficacy with sexual satisfaction.
CONCLUSIONS: Greater sexual problems and lower sexual self-efficacy were associated with poorer psychosocial quality-of-life and sexual satisfaction among postmenopausal breast cancer survivors taking AET. Interventions to address sexual problems and sexual self-efficacy, particularly among unpartnered women, may be beneficial for improving the well-being of postmenopausal breast cancer survivors on AET.

Entities:  

Year:  2019        PMID: 30994574      PMCID: PMC7081279          DOI: 10.1097/GME.0000000000001337

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  65 in total

Review 1.  Marital quality and health: a meta-analytic review.

Authors:  Theodore F Robles; Richard B Slatcher; Joseph M Trombello; Meghan M McGinn
Journal:  Psychol Bull       Date:  2013-03-25       Impact factor: 17.737

2.  Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis.

Authors:  K Lorig; R L Chastain; E Ung; S Shoor; H R Holman
Journal:  Arthritis Rheum       Date:  1989-01

3.  Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline.

Authors:  Jeanne Carter; Christina Lacchetti; Barbara L Andersen; Debra L Barton; Sage Bolte; Shari Damast; Michael A Diefenbach; Katherine DuHamel; Judith Florendo; Patricia A Ganz; Shari Goldfarb; Sigrun Hallmeyer; David M Kushner; Julia H Rowland
Journal:  J Clin Oncol       Date:  2017-12-11       Impact factor: 44.544

Review 4.  How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer.

Authors:  Sharon L Bober; Jennifer B Reese; Lisa Barbera; Andrea Bradford; Kristen M Carpenter; Shari Goldfarb; Jeanne Carter
Journal:  Curr Opin Support Palliat Care       Date:  2016-03       Impact factor: 2.302

Review 5.  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.

Authors:  Caitlin C Murphy; L Kay Bartholomew; Melissa Y Carpentier; Shirley M Bluethmann; Sally W Vernon
Journal:  Breast Cancer Res Treat       Date:  2012-06-12       Impact factor: 4.872

6.  Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.

Authors:  Lesley Fallowfield; David Cella; Jack Cuzick; Stephen Francis; Gershon Locker; Anthony Howell
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

7.  A menopause-specific quality of life questionnaire: development and psychometric properties.

Authors:  J R Hilditch; J Lewis; A Peter; B van Maris; A Ross; E Franssen; G H Guyatt; P G Norton; E Dunn
Journal:  Maturitas       Date:  1996-07       Impact factor: 4.342

8.  The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women.

Authors:  Leonard R Derogatis; Raymond Rosen; Sandra Leiblum; Arthur Burnett; Julia Heiman
Journal:  J Sex Marital Ther       Date:  2002 Jul-Sep

9.  Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Authors:  Lynne I Wagner; Fengmin Zhao; Paul E Goss; Judith-Anne W Chapman; Lois E Shepherd; Timothy J Whelan; Bassam I Mattar; Jose A Bufill; William C Schultz; Irving E LaFrancis; Gauri G Nagargoje; Radhakrishna Vemuri; Daniel A Nikcevich; George W Sledge; David Cella
Journal:  Breast Cancer Res Treat       Date:  2018-02-17       Impact factor: 4.872

Review 10.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Authors:  Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

View more
  4 in total

1.  Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.

Authors:  Debra L Barton; Stephanie L Pugh; Patricia A Ganz; Steven C Plaxe; Bridget F Koontz; Jeanne Carter; Natalya Greyz-Yusupov; Seth J Page; Kendrith M Rowland; Ernie P Balcueva; Sobia Nabeel; Jack B Basil; Matthew L Hill; Carolyn Y Muller; Maria C Bell; Snehal Deshmukh; Lisa A Kachnic
Journal:  J Clin Oncol       Date:  2021-12-09       Impact factor: 44.544

2.  The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy.

Authors:  Haoran Jiang; Yu Dong; Wei Zong; Xiu-Jie Zhang; Hui Xu; Feng Jin
Journal:  BMC Womens Health       Date:  2022-04-27       Impact factor: 2.742

3.  Aromatase Inhibitor Symptom Management Practices: A Retrospective Study.

Authors:  Andrew Ernst; Kathryn E Flynn; Elizabeth M Weil; Bradley H Crotty; Sailaja Kamaraju; Nicole Fergestrom; Joan Neuner
Journal:  Clin Breast Cancer       Date:  2020-07-22       Impact factor: 3.225

4.  Prevalence and predictors of poor sexual well-being over 5 years following treatment for colorectal cancer: results from the ColoREctal Wellbeing (CREW) prospective longitudinal study.

Authors:  Jane Frankland; Sally Wheelwright; Natalia V Permyakova; David Wright; Nicole Collaço; Lynn Calman; Jane Winter; Deborah Fenlon; Alison Richardson; Peter W Smith; Claire Foster
Journal:  BMJ Open       Date:  2020-11-12       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.